Magnil

Magnyl: an effective combination drug for the prevention of cardiovascular diseases

Magnyl, produced by the Danish pharmaceutical company Nycomed, is a combination drug containing acetylsalicylic acid and magnesium hydroxide. This drug belongs to the pharmaceutical group of combined drugs used in the prevention of diseases associated with increased platelet aggregation.

Magnyl is presented on the pharmaceutical market in several dosage forms, including tablets of various dosages and enteric tablets. Magnyl tablets containing 150 mg and 500 mg of acetylsalicylic acid are available, as well as enteric tablets containing 100 mg and 500 mg of this active substance.

The main active ingredient of Magnyl is a combination of acetylsalicylic acid and magnesium hydroxide. The drug has the following indications for use: prevention of diseases accompanied by increased platelet aggregation. Such diseases include thrombosis and embolism, unstable angina, myocardial infarction, ischemic cerebrovascular accidents (including ischemic stroke) and the postoperative period after cardiac and vascular operations, including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty.

However, Magnil has certain contraindications. The drug is not recommended for a history of bleeding in the gastrointestinal tract, a history of cerebral hemorrhage, thrombocytopenia, a tendency to bleed, hemophilia, hemorrhagic diathesis, hypoprothrombinemia, bronchial asthma, erosive and ulcerative lesions of the gastrointestinal tract in the acute phase, deficiency of glucose-6-phosphate dehydrogenase , renal failure, as well as during pregnancy (especially in the first and third trimesters) and during lactation. In addition, Magnyl is contraindicated in children and persons with hypersensitivity to acetylsalicylic acid or salicylates.

Possible side effects of Magnyl include discomfort in the epigastric region. Interactions with other drugs must also be taken into account when using Magnyl. For example, in high doses Magnyl can enhance the effect of anticoagulants, antiplatelet agents, glucocorticosteroids, as well as anti-inflammatory and antirheumatic drugs.

It is important to note that this information is current as of my last update in September 2021, and it is possible that new information about Magnyl has become available after this time. To obtain the most accurate and up-to-date information about the drug Magnyl, it is recommended to consult with a medical specialist or pharmacist who can provide you with detailed information and recommendations on the use of this medicine.